The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Natalie Douglas
Advertisement
Articles by Natalie Douglas
Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5